Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 146-146
Author(s):  
Hiren V. Patel ◽  
Joshua Sterling ◽  
Arnav Srivastava ◽  
Sinae Kim ◽  
Biren Saraiya ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Palliative Care ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage Iv ◽  
Stage Iii ◽  
Care Utilization ◽  
Clinical Factors ◽  
Factors Associated ◽  
Specific Manner

146 Background: Palliative care (PC) offers various benefits for patient with cancer that include, but are not limited to, decrease in disease-specific symptoms and improvement in functional status. Several oncological guidelines have adopted early integration of PC into oncologic care to improve quality of life among patients with advanced malignancies. However, PC utilization patterns and factors associated with its use in advanced renal cell carcinoma (RCC) remain poorly understood. Methods: Using the National Cancer Database (NCDB), we abstracted patients with Stage III and IV RCC from 2004-2014 and evaluated PC utilization amongst this cohort. Socioeconomic and clinical factors were compared for patient receiving and not receiving PC for advanced RCC. Multivariable logistic regression identified factors that were associated with receipt of PC among the overall cohort and treatment-based cohorts. Results: Among 20,122 and 42,014 patients with Stage III and IV RCC, 329 and 9,317 patients received PC, respectively. From 2004 to 2014, PC utilization was stable at ̃1% for Stage III RCC and minimally increased from 17% to 20% for Stage IV RCC. Multivariable analysis demonstrated that increased comorbidities, insurance status, higher education status, facility location, care at a comprehensive cancer program or integrated network, sarcomatoid histology, and prior treatments significantly increased likelihood of palliative care utilization. We uncover socioeconomic and clinical factors that are associated with receipt of palliative care use in a treatment-specific manner. Conclusions: While PC utilization has minimally increased for Stage IV RCC, there are several demographic, socioeconomic, and clinical factors that predict PC use, especially in a treatment-specific manner, among patients with advanced RCC. Taken together, this suggests the need for more equitable and systematic use of PC among patients with advanced RCC.

Factors associated with palliative care (PC) utilization in advanced and metastatic renal cell carcinoma (RCC).

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 297-297
Author(s):  
Hiren V. Patel ◽  
Joshua Sterling ◽  
Arnav Srivastava ◽  
Sinae Kim ◽  
Biren Saraiya ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Palliative Care ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Multivariable Analysis ◽  
Stage Iv ◽  
Stage Iii ◽  
Clinical Factors ◽  
Factors Associated ◽  
To Receive

297 Background: Palliative care (PC) offers various benefits for patient with cancer that include, but are not limited to, decrease in disease-specific symptoms and improvement in functional status. Several oncological guidelines have adopted early integration of PC into oncologic care to improve quality of life among patients with advanced malignancies. However, PC utilization patterns and factors associated with its use in advanced renal cell carcinoma (RCC) remain poorly understood. Methods: Using the National Cancer Database (NCDB), we abstracted patients with stage III and IV RCC from 2004-2014 and evaluated PC utilization amongst this cohort. Socioeconomic and clinical factors were compared for patient receiving and not receiving PC for advanced RCC. Multivariable logistic regression identified factors that were associated with receipt of PC. Results: We identified 20,122 and 42,014 patients with stage III and IV RCC, respectively. Among this cohort, 329 and 9,317 patients received PC for stage III and IV RCC, respectively. From 2004 to 2014, PC utilization has been stable at ~1% for stage III RCC and has significantly increased from 17% to 20% for stage IV RCC. Multivariable analysis demonstrated that Blacks, income >$48,000, regions outside of Northeast, stage III RCC, and patients that received surgery were less likely to receive PC. Patients that were female, with more comorbidities, uninsured or with government insurance, lower educational status, treated at academic or integrated cancer program, with sarcomatoid histology, receiving systemic therapy were more likely to receive PC. Conclusions: While PC utilization has significantly increased for stage IV RCC, there are several demographic, socioeconomic, and clinical factors that predict PC usage among patients with advanced RCC. Taken together, this suggests the need for more equitable and systematic use of PC among patients with advanced RCC.

Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma

2019 ◽  
Vol 17 (2) ◽  
pp. e314-e322
Author(s):  
Alp Tuna Beksac ◽  
Mesude Bicak ◽  
Ishan Paranjpe ◽  
David J. Paulucci ◽  
John P. Sfakianos ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Oncologic Outcome ◽  
Chromophobe Renal Cell Carcinoma ◽  
Stage Iii ◽  
Factors Associated

Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma

2022 ◽  
Vol 2 (1) ◽  
pp. 25-30
Author(s):  
RYO FUJIWARA ◽  
YOSHINOBU KOMAI ◽  
TOMOHIKO OGUCHI ◽  
NOBORU NUMAO ◽  
SHINYA YAMAMOTO ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Treatment Period ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Factors ◽  
First Line ◽  
Factors Associated ◽  
First Line Therapy ◽  
Line Therapy

Background/Aim: To evaluate the relationship between treatment period and overall survival (OS) and to identify clinical factors associated with OS in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods: Two hundred thirteen consecutive patients with mRCC receiving systemic therapy between 2008 and 2020 were divided into two groups: those starting first-line therapy in 2008-2015 (n=133) and those in 2016-2020 (n=80). Clinical factors associated with OS were retrospectively and statistically analyzed. Results: Median OS and one-, three- and five-year OS rates were not reached and 88.7%, 64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and 34.2% in 2008-2015 (p=0.0013). Multivariate analysis identified the period in which first-line therapy was started as the strongest predictor for OS (p=0.0002). Conclusion: OS was significantly better in mRCC patients treated in 2016-2020 than in 2008-2015. Treatment period was the strongest predictor for OS.

scholarly journals Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC)

2021 ◽  
Vol 233 (5) ◽  
pp. e230-e231
Author(s):  
Hiren V. Patel ◽  
Joshua Sterling ◽  
Arnav Srivastava ◽  
Biren Saraiya ◽  
Tina M. Mayer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Palliative Care ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Factors Associated

Factors associated with palliative intervention utilization for metastatic renal cell carcinoma

2022 ◽  
Author(s):  
Hiren V. Patel ◽  
Sinae Kim ◽  
Arnav Srivastava ◽  
Brian M. Shinder ◽  
Joshua Sterling ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Factors Associated

1020 Clinical variables for predicting stage IV renal cell carcinoma patients who will not benefit from cytoreductive nephrectomy

2012 ◽  
Vol 11 (1) ◽  
pp. e1020-e1020a
Author(s):  
Y. Ohno ◽  
J. Nakashima ◽  
M. Ohori ◽  
H. Okubo ◽  
K. Shimodaira ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage Iv ◽  
Cytoreductive Nephrectomy ◽  
Clinical Variables

scholarly journals Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis—A Systematic Review and Pooled Analysis

2021 ◽  
Vol 27 ◽  
Author(s):  
Yuqing Wu ◽  
Saisai Chen ◽  
Minhao Zhang ◽  
Kuangzheng Liu ◽  
Jibo Jing ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Science Studies ◽  
Cox Regression ◽  
Pooled Analysis ◽  
Factors Associated ◽  
T Stage ◽  
Multivariable Analyses ◽  
Xp11.2 Translocation

Purpose: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a rare subtype of renal cell carcinoma (RCC), characterized by translocations of Xp11.2 breakpoints, involving of the transcription factor three gene (TFE3). The aim of our study was to comprehensively characterize the clinical characteristics and outcomes, and to identify risk factors associated with OS and PFS in Xp11.2 tRCC patients.Methods: Literature search on Xp11.2 tRCC was performed using databases such as pubmed EMBASE and Web of Science. Studies were eligible if outcomes data (OS and/or PFS) were reported for patients with a histopathologically confirmed Xp11.2 tRCC. PFS and OS were evaluated using the univariable and multivariable Cox regression model.Results: There were 80 eligible publications, contributing 415 patients. In multivariable analyses, the T stage at presentation was significantly associated with PFS (HR: 3.87; 95% CI: 1.70 to 8.84; p = 0.001). The median time of PFS was 72 months. In the multivariable analyses, age at diagnosis (HR: 2.16; 95% CI: 1.03 to 4.50; p = 0.041), T stage at presentation (HR: 4.44; 95% CI: 2.16 to 9.09; p < 0.001) and metastasis status at presentation (HR: 2.67; 95% CI: 1.12 to 6.41; p = 0.027) were all associated with OS, with a median follow-up time of 198 months.Conclusion: T stage at presentation is the only factor that is associated with both PFS and OS in patients with Xp11.2 tRCC. Also, patients over 45 or with metastases are more likely to have poorer OS.

Sign in / Sign up

Export Citation Format

Share Document